EarlySense, the market leader in Proactive Patient Care Solutions™, announced today that the company has been granted three United States patents. The first, US Patent number , was granted for the ability of the EarlySense technology to monitor and predict congestive heart failure (CHF) and asthma attacks.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on the class action lawsuits filed against the Company alleging possible violations of federal securities laws in relation to the delayed filing of its 10K earlier this year.
Students at the Hebrew University Biodesign program develop a handheld device for rapid and safe IV insertion. Biodesign is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and Hadassah Medical Center in partnership with Stanford University.
A new prototype device for rapid and safe IV insertion reduces pain in hospitalized children. The semi-automatic handheld device, called SAGIV, identifies veins, inserts a needle and withdraws it in a single movement. It was developed by students and clinicians in the Biodesign program of the Hebrew University of Jerusalem and Hadassah Medical Center.
SpineGuard has announced that it has received product certification ("Ninsho") to market its Classic and Curved PediGuard® products in Japan. “This regulatory clearance is the result of a diligent collaborative process with our Japanese partners, notably Surgical Spine Inc...
Unlike humans, planarian flatworms have the remarkable ability to regrow any missing body part, making them an ideal model with which to study the molecular basis of regeneration. Over the years scientists have learned that planarians mount recovery responses that differ depending on the severity of the injury they suffer.
Despite all the research done on Alzheimer’s, there is still no early diagnostic tool for the disease. By looking at the brain wave components of individuals with the disease, Professor Tiago H. Falk of INRS’s Centre Énergie Matériaux Télécommunications has identified a promising avenue of research that may not only help diagnose the disease, but also assess its severity.
New Medical Device Polymer Biocompatibility Screening Test Using Zebrafish Embryos to be Discussed at AMI's Medical Grade Polymers 2013September 3, 2013 10:13 am | by Business Wire | Microtest Laboratories, Inc. | News | Comments
A new test that utilizes Zebrafish (Danio rerio) embryos to screen plastics, composites, and polymers for toxicity in medical device manufacturing will be featured at AMI’s Medical Grade Polymer 2013 technical conference in September. Dr. Richter developed the new “ZET Medical Device Polymer Biocompatibility Screen Test,” at Microtest Laboratories for use by medical device manufacturers and bio-material researchers.
Nanoscale "cages" made from strands of DNA can encapsulate small-molecule drugs and release them in response to a specific stimulus, McGill University researchers report in a new study. The research, published online Sept. 1 in Nature Chemistry, marks a step toward the use of biological nanostructures to deliver drugs to diseased cells in patients.
Sonendo, the developer of a revolutionary technology for the endodontic marketplace, announced today that the company has received 510(k) FDA clearance for the first generation of its Multisonic Ultracleaning System™ set to launch in 2014. The device is designed to be a minimally invasive, disruptive technology that uses multiple wavelengths of sound to simultaneously clean the entire root canal system.
A team of University of California, Riverside researchers have developed a novel transparent skull implant that literally provides a "window to the brain", which they hope will eventually open new treatment options for patients with life-threatening neurological disorders, such as brain cancer and traumatic brain injury.
A study estimates that total annual costs for five major healthcare-associated infections (HAIs) were $9.8 billion, with surgical site infections contributing the most to overall costs, according to a report published by JAMA Internal Medicine, a JAMA Network publication.
Biomet amended its Q4 and annual earnings report to reflect a swing to red in Q4 and much deeper losses for the full year compared to earlier reports. The Warsaw, Ind.-based orthopedics company posted losses of $221.2 million on $784 million in sales during the 3-month period ended May 31, 2013.
Texas mobile health startup Vital Art & Science is looking for a pharmaceutical industry partner now that it's raised $550,000 in support of its MyVisionTrack iPhone hyperacuity test. MyVisionTrack is an FDA-cleared smartphone app for detecting age-related macular degeneration and other age-related visual impairments.
Medtronic Announces Formation of Hospital Solutions Business Aimed at Driving Efficiencies and Cost SavingsSeptember 2, 2013 12:06 pm | by The Associated Press | News | Comments
Medtronic, Inc. (NYSE: MDT) today announced the formation of Medtronic Hospital Solutions, a new business focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency. The new business will focus initially on offering services in Europe...